ANVS (biotech) - December 2024ANVS is a clinical-stage biotech company, working on a drug for Alzheimer's Disease (AD). I believe in their approach toward AD, compared to all the other companies that are trying to remove amyloid plaques, which doesn't help fight AD. Check out annovisbio.com/our-science for more of the scientific stuff.
Suffice to say, I believe in the science behind these guys so I think they are safe from going to 0 in the immediate future. That's about as good as you can hope, from a clinical-stage biotech!
For the immediate future, and I'm just talking this month December 2024, I think it could have a strong return this month. Watch the 34-period ema in 65-minute chart (you can use 60-minute chart if you do not have a paid plan, as an approximation).
Current price $7.28, at market close on first day of December (+8.5% today).
